A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)

Trial Profile

A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Camptothecin (Primary) ; Bevacizumab
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Cerulean Pharma
  • Most Recent Events

    • 11 Sep 2017 Results assessing safety and efficacy of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma, were published in the Annals of Oncology.
    • 10 Jun 2017 Biomarkers information updated
    • 17 Aug 2016 According to a Cerulean Pharma media release, the full data set from the trial are expected to be submitted for presentation at an upcoming medical conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top